Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Gardasil, which prevents cancers caused by the ... compared with analyst forecasts of around $7.4 billion.

Gardasil is a vaccine that prevents cancer from ... cats and cattle, posted nearly $1.4 billion in sales, up 9% from the same period a year ago. The company said higher pricing for products ...

to 4.6% in 2025 and 4.5% in 2026. A collapse in the Chinese housing market has undermined consumer confidence. Overall sales of Gardasil fell 17% to $1.55 billion in the final quarter of last year ...

Gardasil was 13% of Merck’s sales in 2024 ... We anticipate peak sales for pulmonary hypertension drug Winrevair around $4 billion, and we’re bullish on the mRNA-based Keytruda combination ...